- Home
- NSTS vs RFL Comparison
NSTS vs RFL Comparison
Compare NSTS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NSTS | RFL |
|---|---|---|
| Founded | 1921 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 61.1M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NSTS | RFL |
|---|---|---|
| Price | $12.11 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.2K | ★ 103.5K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | $256,000.00 | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $10.73 | $1.12 |
| 52 Week High | $13.06 | $3.19 |
Technical Indicators
Market Signals| Indicator | NSTS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 52.39 |
| Support Level | $11.91 | $1.35 |
| Resistance Level | $12.30 | $1.38 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 32.73 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.